Veristat, Molecular Templates enter into preferred provider agreement for refractory non-Hodgkin’s B-Cell Lymphoma trial
"We are elated following the FDA’s approval of our IND application for MT-3724 and are eager to begin the next steps of our clinical journey with Veristat. Veristat
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.